![Pioglitazone.svg](https://upload.wikimedia.org/wikipedia/commons/thumb/a/ad/Pioglitazone.svg/271px-Pioglitazone.svg.png)
Tuesday, January 31, 2017
Clinical trial finds pioglitazone drug safe and effective for NASH patients
![Pioglitazone.svg](https://upload.wikimedia.org/wikipedia/commons/thumb/a/ad/Pioglitazone.svg/271px-Pioglitazone.svg.png)
Monday, December 13, 2010
Pioglitazone, may halt the growth of cysts in Polycystic Kidney Disease....
Recently, researchers from the schools of Science and Medicine at Indiana University-Purdue University Indianapolis and colleagues from the Mayo Clinic reported that drug Pioglitazone, (see structure Enantiomers) commonly used to treat diabetes may also retard the growth of fluid-filled cysts of the most common genetic disorder, polycystic kidney disease.
Using a rat model that has the same genetic mutation as a form of human PKD, the two research groups independently tested a pioglitazone treatment regimen and found that it slowed down both kidney and liver cyst growth by inhibiting a chloride channel in the cells of these organs. Authors claim that the, though the idea of using a chloride channel inhibitor to treat PKD is not new, but usage of an insulin sensitizing agent like piogltiazone inhibits chloride channels is new. The finding that pioglitazone, which has already been approved by the Food and Drug Administration for diabetes, can halt cyst progression and may be an effective and well-tolerated treatment for this chronic disease, is exciting. Confirmation of these results in other animal models of PKD would be a useful next step.....
Saturday, January 26, 2013
Takeda Receives FDA Approval for Oseni (alogliptin and pioglitazone) for Type 2 Diabetes
Tuesday, June 18, 2013
Diabetes drug shows promise in treatment of neurodegenerative disease
Friday, January 22, 2010
Encouraging results from first phase III clinical trials of Balaglitazone (an anti-diabetic drug)......
All three active arms showed good tolerability and adverse event profile, with Balaglitazone 10mg demonstrating less water retention, less fat accumulation, lower weight/BMI gain and less bone loss when compared to the Pioglitazone arm.
Encourged by these results both companies (Dr. Reddy's & Rheoscience) are planning for detailed studies required for registration of Balaglitazone.
Type 2 diabetes is a major cause of morbidity and mortality in the industrialized world, with cardiovascular disease as the leading cause of death, accounting for almost 50% of all T2D deaths. Furthermore, the number of T2D patients is increasing rapidly, and the number of patients is expected to reach between 300 and 380 million by 2025, thereby placing an enormous economical burden on global healthcare. Hope new drugs will take care of this problem.
Ref : http://www.drreddys.com/media/popups/jan4_2010.html
Thursday, July 26, 2012
Investigational diabetes drug appears to improve insulin sensitivity without side effects
"Current diabetes medications activate a receptor that improves insulin sensitivity, but unfortunately also contributes to side effects that make some people discontinue the medication, contributing to other health problems," says principal investigator Brian N. Finck, PhD. "So even though these drugs are effective, we'd really like to find new insulin-sensitizing therapies that would avoid activating the same receptor."